Hepatitis B Therapeutics in Major Developed Industrial and Market studiess to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Industrial and Market studies Growth
"Hepatitis
B Therapeutics in Major Developed Markets to 2021 - Increasing Number
of Migrants from High-Prevalence Regions to Drive Market Growth"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Hepatitis
B is an infectious liver disease caused by the Hepatitis B Virus
(HBV) and characterized by acute or chronic inflammation of the
liver. Despite its status as a vaccine-preventable disease, it
remains a serious global health concern. Incidence tends to be higher
in countries with a significant number of migrants from medium and
high-prevalence countries. Approximately 350 million people worldwide
are infected with chronic hepatitis B, which causes significant
morbidity and mortality. Around 780,000 patients die from hepatitis B
each year, of which 650,000 deaths are due to complications such as
cirrhosis and liver cancer. Despite this, diagnosis and treatment
rates are poor, stemming from its asymptomatic nature.
Globally,
the hepatitis B therapeutics market is served moderately well by the
available products, of which Baraclude and Viread are the most
frequently prescribed. However, both have received black-box warnings
from the US Food and Drug Administration (FDA), meaning that the
market has a high level of unmet need.
Scope
- The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons.
- Will these drugs continue to dominate hepatitis B treatment?
- With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline.
- What are the most prominent small molecules and vaccines in the pipeline?
- Do the pipeline molecules offer advantages over commercially proven mechanisms?
- Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
- Over the 2014
Table
of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Classification 9
2.2 Pathophysiology 9
2.3 Etiology 11
2.4 Symptoms 12
2.5 Diagnosis 12
2.6 Epidemiology 13
2.1 Classification 9
2.2 Pathophysiology 9
2.3 Etiology 11
2.4 Symptoms 12
2.5 Diagnosis 12
2.6 Epidemiology 13
Comments
Post a Comment